Learn

Psoriasis Research Review Issue 119 with commentary by Associate Professor John Frew.

This review is a unique Australian publication providing topical, relevant and accessible information for health professionals with an interest in psoriasis. In essence, the review is a summary of what we consider to be some of the most significant new studies in this area.

Details

In this issue we feature:

-  Identifying systemic treatment candidates using IPC guidelines
-  Femoral atherosclerotic plaque in psoriasis patients
-  Home- vs office-based narrowband UV-B phototherapy
-  Safety and efficacy of deucravacitinib up to 3 years
-  Psoriasis risk with immune checkpoint inhibitors
-  Risankizumab for palmoplantar psoriasis
-  Age effects on drug survival rates of IL-17 and IL-23 inhibitors
-  Bimekizumab efficacy in scalp, nail, and palmoplantar psoriasis
-  Switching from ustekinumab to guselkumab in partial responders with psoriasis
-  Long-term efficacy and safety of biologics for plaque psoriasis

To access this publication please click ‘Enrol Now’ and you’ll be directed to  the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.